Company profile
Climb Bio, Inc.
NASDAQ: CLYM · Healthcare · Biotechnology
PublicHQ Wellesley Hills, DECIK 0001768446Reports USD
#1 of 1,417 Healthcare companies by revenue
EA Score
——FH 62DQ —GM —SS 46
v0.1 · 35/100 weight · pillars only
↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$59.9M
Employees
28
as of 2026-08-10
Market cap
$801.7M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$59.9M-$59.9M2025
Operating income-$67.9M-$67.9M2025
Total assets$167.7M$167.7M2025
Liabilities$7.3M$7.3M2025
Equity$160.5M$160.5M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Climb Bio, Inc.’s financial profile?
Climb Bio, Inc. earned -$59.9M in FY2025 net income.
Peers · Healthcare
Annexon, Inc.——Faeth Therapeutics, Inc.——Aura Biosciences, Inc.——Bright Minds Biosciences Inc.——SpyGlass Pharma, Inc. Common Stock——BridgeBio Oncology Therapeutics Inc.——Key facts
CEOAoife Brennan BCh MMSc
SectorHealthcare
IndustryBiotechnology
HeadquartersWellesley Hills, DE
ExchangeNASDAQ: CLYM
Employees28
IPO date2021-08-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.